Lipohypertrophy and glomerulonephritis after the use of aprotinin in an insulin-dependent diabetic.
Boag
F
F
Chappell
M
M
Beckett
A G
AG
Dandona
P
P
D000273:Adipose Tissue / Q000473:pathology*; D000293:Adolescent; D007611:Aprotinin / Q000009:adverse effects*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D005260:Female; D005921:Glomerulonephritis / Q000139:chemically induced*; D006801:Humans; D006984:Hypertrophy; D007333:Insulin Resistance
D007611:Aprotinin